Preferred Name |
Abciximab |
|
Synonyms |
|
|
Definitions |
A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation. Abciximab binds to the GP IIb/IIIa receptor on the platelet membrane, which inhibits the binding of fibrinogen to the GP IIb/IIIa receptor. This prevents both platelet aggregation and thrombus formation. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C76128 |
|
Accepted_Therapeutic_Use_For |
as an adjunct to aspirin and heparin for the prevention of acute cardiac ischemic complications |
|
CAS_Registry |
143653-53-6 |
|
code |
C76128 |
|
Contributing_Source |
FDA |
|
definition |
A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation. Abciximab binds to the GP IIb/IIIa receptor on the platelet membrane, which inhibits the binding of fibrinogen to the GP IIb/IIIa receptor. This prevents both platelet aggregation and thrombus formation. |
|
FDA_UNII_Code |
X85G7936GV |
|
in_subset | ||
label |
Abciximab |
|
Legacy Concept Name |
Abciximab |
|
Preferred_Name |
Abciximab |
|
prefixIRI |
NCIT:C76128 |
|
prefLabel |
Abciximab |
|
Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
UMLS_CUI |
C0288672 |
|
subClassOf |